Zanidatamab data demonstrate clinical potential of novel bispecific antibody in HER2-targeted biliary tract and gastric cancers
Additional presentations, including a lurbinectedin oral presentation in small cell lung cancer (SCLC), underscore the strength of Jazz's solid tumor portfolio and the company's commitment to address difficult-to-treat tumors
Read more at prnewswire.com